Last reviewed · How we verify
Human Plasma-Derived Fibrinogen Concentrate
At a glance
| Generic name | Human Plasma-Derived Fibrinogen Concentrate |
|---|---|
| Also known as | FIB Grifols |
| Sponsor | Grifols Therapeutics LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
- FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis (PHASE3)
- Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: